Maybe it will become public later on.
I hope so. I have no idea what the secrecy around these hurdles achieves. It is common practice to disclose the efficacy boundaries, and investors deserve to have a sense of what's going on. Disclosing these boundaries reveals nothing about the actual success or failure of the trial. All is does is breed speculation and misdirection about the real nature of this trial.